- Home
- GSIW vs CLRB Comparison
GSIW vs CLRB Comparison
Compare GSIW & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- CLRB
- Stock Information
- Founded
- GSIW 2016
- CLRB 2002
- Country
- GSIW Hong Kong
- CLRB United States
- Employees
- GSIW N/A
- CLRB N/A
- Industry
- GSIW
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- GSIW
- CLRB Health Care
- Exchange
- GSIW Nasdaq
- CLRB Nasdaq
- Market Cap
- GSIW 10.5M
- CLRB 10.7M
- IPO Year
- GSIW 2023
- CLRB N/A
- Fundamental
- Price
- GSIW $0.57
- CLRB $0.25
- Analyst Decision
- GSIW
- CLRB Buy
- Analyst Count
- GSIW 0
- CLRB 2
- Target Price
- GSIW N/A
- CLRB $28.00
- AVG Volume (30 Days)
- GSIW 156.5K
- CLRB 3.9M
- Earning Date
- GSIW 12-31-2024
- CLRB 11-18-2024
- Dividend Yield
- GSIW N/A
- CLRB N/A
- EPS Growth
- GSIW N/A
- CLRB N/A
- EPS
- GSIW N/A
- CLRB N/A
- Revenue
- GSIW $1,408,469.00
- CLRB N/A
- Revenue This Year
- GSIW N/A
- CLRB N/A
- Revenue Next Year
- GSIW N/A
- CLRB N/A
- P/E Ratio
- GSIW N/A
- CLRB N/A
- Revenue Growth
- GSIW N/A
- CLRB N/A
- 52 Week Low
- GSIW $0.53
- CLRB $0.23
- 52 Week High
- GSIW $15.99
- CLRB $4.45
- Technical
- Relative Strength Index (RSI)
- GSIW 36.17
- CLRB 5.84
- Support Level
- GSIW $0.55
- CLRB $0.23
- Resistance Level
- GSIW $0.64
- CLRB $0.28
- Average True Range (ATR)
- GSIW 0.06
- CLRB 0.07
- MACD
- GSIW 0.04
- CLRB -0.11
- Stochastic Oscillator
- GSIW 16.67
- CLRB 1.41
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.